LivingGLP1
parallel randomized trial

S003056

Type 2 diabetes (adults)S003056

Design

Randomized
40
Start year
2011
Treatment
Countries
Japan (2 sites)
Sponsor
(non industry)
Eligibility
age 20 to 85; HbA1c 6.9 to 16.6 percent on sulfonylurea; no insulin

Conduct and analysis

Blinding
open label
Sequence generation
computer
Allocation concealment
central
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
completers
Missing data
completers only

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Exenatide 5 ug subcutaneous twice daily
Exenatide 5 ug twice daily
glimepiride; lifestyle: standard2118
A2liraglutide
Liraglutide 0.3 to 0.9 mg once daily
glimepiride in 16, glibenclamide in 1; lifestyle: standard1917

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticExenatide 5 ug subcutaneous twice daily
A1
Liraglutide 0.3 to 0.9 mg once daily
A2
agemean (years)61.161.9
agesd (years)10.39.9
bmimean (kg/m2)27.725.3
bmisd (kg/m2)5.53.4
diabetes durationmean (years)6.210.5
diabetes durationsd (years)6.28.6
egfrmean (mL/min/1.73 m2)77.382.1
egfrsd (mL/min/1.73 m2)9.619.2
femalen66
hba1cmean (percent)9.610.1
hba1csd (percent)1.32.0
uacrmean (mg/gCr)57.189.5
uacrsd (mg/gCr)139.5137.4

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (2 lines; O25)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / not stated; other; R0022533:Results
A2events0 / not stated; other; R0022533:Results
Discontinuation due to adverse events (2 lines; O26)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / not stated; other; R0022533:Results
A2events0 / not stated; other; R0022533:Results
Discontinuation due to gastrointestinal adverse events (2 lines; O27E)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events0 / not stated; other; R0022533:Results
A2events0 / not stated; other; R0022533:Results